Companies / GANX Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Ticker GANX Exchange Nasdaq Sector Healthcare Industry Biotechnology Market cap $44.64M 52-week range $0.94 - $4.34 Valuation Share price $1.03 (close of Nov 6, 2026) P/E (TTM) -2.02x Price to book 3.95x Price to free cash flow -2.36x Enterprise value $32.17M Book value per share $0.26 Price performance Period Change 1 day +7.29% 5 days -8.85% 1 month -38.32% 3 months -42.13% 6 months -46.07% Year to date -68.01% 1 year -45.79% 3 years -62.82% 5 years -86.78% All time -91.56%
Short interest As of Oct 15, 2026 Short % of float 7.49% Shares short 3.19M Days to cover 6.51 Change since prior report +4.43% Source FINRA consolidated short interest Profitability and growth Return on equity -108.60% Return on invested capital -96.96% Return on assets -88.35% Return on capital employed -96.12% Cash flow and balance sheet Free cash flow yield (TTM) -42.46% Current ratio 4.36x Net debt to EBITDA 0.65x Latest reported year Period end Dec 31, 2025 Fiscal year 2025 EBITDA -$18.62M Net income -$20.16M Earnings per share $-0.61 Research and development $10.21M Shares outstanding 32.97M Income statement by year Period end Revenue Net income EPS 2025-12-31 - -$20.16M -$0.61 2024-12-31 - -$20.41M -$0.89 2023-12-31 $55.18K -$22.27M -$1.71 2022-12-31 $140.11K -$17.59M -$1.48 2021-12-31 $164.99K -$13.89M -$1.37 2020-12-31 $28.88K -$3.58M -$1.33 2019-12-31 $41.30K -$2.19M - 2018-12-31 $20.61K -$1.11M -
Margins and returns by year Period end Net margin Return on equity Return on capital 2025-12-31 - -108.60% -96.96% 2024-12-31 - -278.10% -254.62% 2023-12-31 -40,354.33% -177.03% -163.56% 2022-12-31 -12,555.13% -93.17% -88.21% 2021-12-31 -8,418.86% -39.90% -37.96% 2020-12-31 -12,387.67% -57.69% -46.62% 2019-12-31 -5,310.88% - - 2018-12-31 -5,364.36% - -290.11%
Cash and debt by year Period end Cash Debt 2025-12-31 $20.84M $300.08K 2024-12-31 $10.39M $328.33K 2023-12-31 $16.80M $449.05K 2022-12-31 $7.31M $495.26K 2021-12-31 $36.88M $590.47K 2020-12-31 $7.49M $715.66K 2019-12-31 $303.32K - 2018-12-31 $400.69K -
Free cash flow by year Period end Free cash flow Stock-based compensation 2025-12-31 -$18.47M $1.80M 2024-12-31 -$18.90M $2.39M 2023-12-31 -$18.88M $3.26M 2022-12-31 -$14.81M $1.53M 2021-12-31 -$12.46M $839.37K 2020-12-31 -$3.26M $81.64K 2019-12-31 -$1.88M - 2018-12-31 -$752.50K -
Investor relations Next earnings report Next confirmed report Nov 11, 2026 Consensus EPS estimate $-0.13 Past earnings dates Reported Fiscal period EPS estimate 2026-08-11 Jun 2026 -$0.14 2026-05-11 Mar 2026 -$0.13 2026-03-26 Dec 2025 -$0.14 2025-11-12 Sep 2025 -$0.15 2025-08-12 Jun 2025 -$0.17 2025-05-14 Mar 2025 -$0.16 2025-03-27 Dec 2024 -$0.18 2024-11-14 Sep 2024 -$0.23
Filings and sources Company website gaintherapeutics.com SEC filings 10-K, 10-Q and 8-K on EDGAR Earnings calendar All upcoming reports Similar companies Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades